Gain Therapeutics (GANX) Deferred Taxes (2020 - 2025)

Gain Therapeutics has reported Deferred Taxes for 6 years, with the latest figure at -$14843.0 in Q4 2025.

• On a quarterly basis, Deferred Taxes rose 98.34% year-over-year to -$14843.0 in Q4 2025; TTM through Dec 2025 was -$328071.0, a 61.62% increase from a year earlier, with the FY2025 full-year figure at -$328071.0, up 61.62% from the prior year.
• Deferred Taxes was -$14843.0 for Q4 2025 at Gain Therapeutics, up from -$18239.0 in the prior quarter.
• The five-year high for Deferred Taxes was $1.6 million in Q2 2023, with the low at -$896566.0 in Q4 2024.
• Average Deferred Taxes over 5 years is -$13556.6, with a median of -$48167.0 recorded in 2021.
• The sharpest annual moves came in 2023 and 2025: Deferred Taxes soared 1440.01% in 2023, then tumbled 113909.94% in 2025.
• Over 5 years, Deferred Taxes stood at -$53507.0 in 2021, then soared by 98.86% to -$608.0 in 2022, then plunged by 62139.97% to -$378419.0 in 2023, then slumped by 136.92% to -$896566.0 in 2024, then soared by 98.34% to -$14843.0 in 2025.
• The last three Deferred Taxes figures came in at -$14843.0 (Q4 2025), -$18239.0 (Q3 2025), and -$206358.0 (Q2 2025), per Business Quant data.